Company intelligence / Profile preview

Cullinan MICA

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Cullinan MICA’s lead candidate, CLN-619, is a humanized IgG1 monoclonal antibody targeting MICA/MICB. It is being tested in Phase 1 trials for relapsed/refractory multiple myeloma and advanced solid tumors, aiming to overcome immune evasion by restoring tumor cell recognition and promoting NK/T cell-mediated lysis. Early studies show a clean safety profile in non-human primates

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Avalon VenturesBregua CorporationMyeloma Investment Fund (Multiple Myeloma Research Foundation)PDI Therapeutics

Beyond the preview

Go deeper on Cullinan MICA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cullinan MICA.

Explore the full profile